Search Result

Results for "

anti-myeloma

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (2) Antibody-Drug Conjugates (ADCs) (1) Apoptosis (14) Autophagy (5) BMI1 (2) Dipeptidyl Peptidase (1) E1/E2/E3 Enzyme (1) JAK (1) Molecular Glues (1) NF-κB (2) Notch (1) PDI (2) Pim (2) STAT (1) γ-secretase (1)
By Research Areas:	Cancer (19) Cardiovascular Disease (1)

Inhibitors & Agonists

Inhibitory Antibodies

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P3239

Belantamab mafodotin GSK2857916; Belantamab mafodotin-blm	Antibody-Drug Conjugates (ADCs)	Cancer
Belantamab mafodotin (GSK2857916) is composed of humanized and focused monoclonal antibody against B cell maturation antigen (BCMA) and McMMAF. Belantamab mafodotin has anti-myeloma activity .

HY-130603

DCZ0415 4 Publications Verification	NF-κB Apoptosis	Cancer
DCZ0415, a potent TRIP13 inhibitor, impairs nonhomologous end joining repair and inhibits NF-κB activity. DCZ0415 induces anti-myeloma activity in vitro, in vivo, and in primary cells derived from drug-resistant myeloma patients .

HY-N0714A

Berbamine dihydrochloride 5+ Cited Publications	NF-κB Autophagy Apoptosis	Cancer
Berbamine dihydrochloride is an inhibitor of NF-κB activity with remarkable anti-myeloma efficacy.

HY-19934A

Pifusertib hydrochloride TAS-117 hydrochloride	Akt Apoptosis Autophagy	Cancer
Pifusertib (TAS-117) hydrochloride is a potent, selective, orally active allosteric Akt inhibitor (with IC₅₀s of 4.8, 1.6, and 44 nM for Akt1, 2, and 3, respectively). Pifusertib hydrochloride triggers anti-myeloma activities and enhances fatal endoplasmic reticulum (ER) stress induced by proteasome inhibition. Pifusertib hydrochloride induces apoptosis and autophagy .

HY-116304

1G244 3 Publications Verification	Dipeptidyl Peptidase Apoptosis	Cancer
1G244 is a potent DPP8/9 inhibitor with IC₅₀s of 12 nM and 84 nM, respectively. 1G244 does not inhibit DPPIV and DPPII. 1G244 induces apoptosis in multiple myeloma cells and has anti-myeloma effects .

HY-15888

PTC-209 Maximum Cited Publications 10 Publications Verification	BMI1 Autophagy	Cancer
PTC-209 is a specific BMI-1 inhibitor with an IC₅₀ of 0.5 μM in HEK293T cell line. PTC-209 irreversibly impairs colorectal cancer-initiating cells (CICs). PTC-209 shows potent anti-myeloma activity and impairs the tumor microenvironment .

HY-15888A

PTC-209 hydrobromide Maximum Cited Publications 10 Publications Verification	BMI1 Autophagy	Cancer
PTC-209 hydrobromide is a specific BMI-1 inhibitor with an IC₅₀ of 0.5 μM in HEK293T cell line. PTC-209 hydrobromide irreversibly impairs colorectal cancer-initiating cells (CICs). PTC-209 hydrobromide shows potent anti-myeloma activity and impairs the tumor microenvironment .

HY-124858

SC99	STAT JAK Apoptosis	Cardiovascular Disease Cancer
SC99 is an orally active, selective STAT3 inhibitor targeting JAK2-STAT3 pathway. SC99 docks into the ATP-binding pocket of JAK2. SC99 inhibits phosphorylation of JAK2 and STAT3 with no effects on the other kinases associated with STAT3 signaling. SC99 inhibits platelet activation, aggregation and displays potent anti-myeloma, anti-thrombotic activities .

HY-19934

Pifusertib TAS-117	Akt Apoptosis Autophagy	Cancer
Pifusertib (TAS-117) is a potent, selective, orally active allosteric Akt inhibitor (with IC₅₀s of 4.8, 1.6, and 44 nM for Akt1, 2, and 3, respectively). Pifusertib triggers anti-myeloma activities and enhances fatal endoplasmic reticulum (ER) stress induced by proteasome inhibition. Pifusertib induces apoptosis and autophagy .

HY-145428

BT-GSI	Notch γ-secretase	Cancer
BT-GSI is a γ-secretase inhibitor (GSI) and a bone-targeted Notch inhibitor. BT-GSI has dual anti-myeloma and anti-resorptive properties, which can be used for the research of multiple myeloma and associated bone disease. BT-GSI inhibits tumor growth and osteolytic disease progression .

HY-122895

E64FC26 2 Publications Verification	Apoptosis PDI	Cancer
E64FC26 is a potent pan-inhibitor of the protein disulfide isomerase (PDI) family, with IC₅₀s of 1.9, 20.9, 25.9, 16.3, and 25.4 μM against PDIA1, PDIA3, PDIA4, TXNDC5, and PDIA6, respectively. E64FC26 shows anti-myeloma activity .

HY-122895A

(E/Z)-E64FC26	Apoptosis PDI	Cancer
(E/Z)-E64FC26 is a mixture complex of E-E64FC26 and Z-E64FC26. E64FC26 (E-E64FC26) is a potent pan-inhibitor of the protein disulfide isomerase (PDI) family, with IC₅₀s of 1.9, 20.9, 25.9, 16.3, and 25.4 μM against PDIA1, PDIA3, PDIA4, TXNDC5, and PDIA6. E64FC26 shows anti-myeloma activity .

HY-129395

Mezigdomide CC-92480	E1/E2/E3 Enzyme Molecular Glues Apoptosis	Cancer
Mezigdomide (CC-92480), a cereblon E3 ubiquitin ligase modulating agent (CELMoD), acts as a molecular glue. Mezigdomide shows high affinity to cereblon, resulting in potent antimyeloma activity .

HY-19322B

PIM-447 dihydrochloride 5 Publications Verification LGH447 dihydrochloride	Pim Apoptosis	Cancer
PIM447 dihydrochloride (LGH447 dihydrochloride) is a potent, orally available, and selective pan-PIM kinase inhibitor, with K_i values of 6, 18, and 9 pM for PIM1, PIM2, and PIM3, respectively. PIM447 dihydrochloride displays dual antimyeloma and bone-protective effects. PIM447 dihydrochloride induces apoptosis .

HY-19322

PIM447 5 Publications Verification LGH447	Pim Apoptosis	Cancer
PIM447 (LGH447) is a potent, orally available, and selective pan-PIM kinase inhibitor, with K_i values of 6, 18, and 9 pM for PIM1, PIM2, and PIM3, respectively. PIM447 displays dual antimyeloma and bone-protective effects. PIM447 induces apoptosis .

HY-144129

hGGPPS-IN-2	Apoptosis	Cancer
hGGPPS-IN-2 (Compound 16g) is a potent inhibitor of the human geranylgeranyl pyrophosphate synthase (hGGPPS). hGGPPS-IN-2 is an analogue of C-2-substituted thienopyrimidine-based bisphosphonates (C2-ThP-BPs). hGGPPS-IN-2 induces target-selective apoptosis of multiple myeloma (MM) cells and exhibits antimyeloma activity in vivo .

HY-144130

hGGPPS-IN-3	Apoptosis	Cancer
hGGPPS-IN-3 (Compound 13h) is a potent inhibitor of the human geranylgeranyl pyrophosphate synthase (hGGPPS). hGGPPS-IN-3 is an analogue of C-2-substituted thienopyrimidine-based bisphosphonates (C2-ThP-BPs). hGGPPS-IN-3 induces target-selective apoptosis of multiple myeloma (MM) cells and exhibits antimyeloma activity in vivo .

HY-144128

hGGPPS-IN-1	Apoptosis	Cancer
hGGPPS-IN-1 (Compound 18b) is a potent inhibitor of the human geranylgeranyl pyrophosphate synthase (hGGPPS). hGGPPS-IN-1 is an analogue of C-2-substituted thienopyrimidine-based bisphosphonates (C2-ThP-BPs). hGGPPS-IN-1 induces target-selective apoptosis of multiple myeloma (MM) cells and exhibits antimyeloma activity in vivo .

Cat. No.	Product Name	Target	Research Area

HY-P3239

Belantamab mafodotin GSK2857916; Belantamab mafodotin-blm	Antibody-Drug Conjugates (ADCs)	Cancer
Belantamab mafodotin (GSK2857916) is composed of humanized and focused monoclonal antibody against B cell maturation antigen (BCMA) and McMMAF. Belantamab mafodotin has anti-myeloma activity .

HY-P9965

Elotuzumab HuLuc 63; PDL 063; BMS 901608	Inhibitory Antibodies	Cancer
Elotuzumab is a monoclonal antibody directed against the SLAMF7 receptor. Elotuzumab has no significant antimyeloma activity when given as a single agent with relapsed or refractory multiple myeloma (RRMM). Elotuzumab results in improved response and outcome when combined with other antimyeloma agents .

Berbamine dihydrochloride 5+ Cited Publications	Alkaloids Structural Classification Monophenols other families Classification of Application Fields Source classification Phenols Plants Isoquinoline Alkaloids Disease Research Fields Cancer	NF-κB Autophagy Apoptosis
Berbamine dihydrochloride is an inhibitor of NF-κB activity with remarkable anti-myeloma efficacy.

Elotuzumab HuLuc 63; PDL 063; BMS 901608	Classification of Application Fields Disease Research Fields Cancer	Others
Elotuzumab is a monoclonal antibody directed against the SLAMF7 receptor. Elotuzumab has no significant antimyeloma activity when given as a single agent with relapsed or refractory multiple myeloma (RRMM). Elotuzumab results in improved response and outcome when combined with other antimyeloma agents .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.

anti-myeloma

Inhibitors & Agonists

Inhibitory Antibodies

NaturalProducts

Natural
Products